RAZTAMRI Trademark

Trademark Overview

On Friday, March 24, 2023, a trademark application was filed for RAZTAMRI with the United States Patent and Trademark Office. The USPTO has given the RAZTAMRI trademark a serial number of 97855551. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 18, 2025. This trademark is owned by SYROS Pharmaceuticals, Inc.. The RAZTAMRI trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical products for the treatment of hematologic cancers; pharmaceuticals for treatment of a myelodysplastic syndrome; pharmaceuticals for treatment of acute myeloid leukemia, which is also known as acute myelogenous leukemia and acute nonlymphocytic leukemia
raztamri

General Information

Serial Number97855551
Word MarkRAZTAMRI
Filing DateFriday, March 24, 2023
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 18, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 3, 2024

Trademark Statements

Goods and Servicespharmaceutical products for the treatment of hematologic cancers; pharmaceuticals for treatment of a myelodysplastic syndrome; pharmaceuticals for treatment of acute myeloid leukemia, which is also known as acute myelogenous leukemia and acute nonlymphocytic leukemia

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, April 16, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSYROS Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140
Party NameSYROS Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140

Trademark Events

Event DateEvent Description
Sunday, April 16, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 28, 2023NEW APPLICATION ENTERED
Tuesday, December 19, 2023ASSIGNED TO EXAMINER
Sunday, December 24, 2023NON-FINAL ACTION WRITTEN
Sunday, December 24, 2023NON-FINAL ACTION E-MAILED
Sunday, December 24, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, April 10, 2024EXAMINERS AMENDMENT -WRITTEN
Wednesday, April 10, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, April 10, 2024EXAMINERS AMENDMENT E-MAILED
Wednesday, April 10, 2024EXAMINER'S AMENDMENT ENTERED
Wednesday, April 10, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 24, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 7, 2024TEAS PETITION TO DIRECTOR RECEIVED
Tuesday, May 14, 2024PUBLISHED FOR OPPOSITION
Friday, August 2, 2024ASSIGNED TO PETITION STAFF
Tuesday, May 14, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, May 22, 2024WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST
Tuesday, August 6, 2024JURISDICTION RESTORED TO EXAMINING ATTORNEY
Tuesday, August 6, 2024PETITION TO DIRECTOR GRANTED
Friday, November 8, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, November 8, 2024PREVIOUS ALLOWANCE COUNT WITHDRAWN
Wednesday, November 27, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 3, 2024PUBLISHED FOR OPPOSITION
Tuesday, December 3, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 14, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, August 18, 2025ABANDONMENT - NO USE STATEMENT FILED
Monday, August 18, 2025ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

raztamri leukemia treatment acute pharmaceuticals which also known nonlymphocytic myelogenous syndrome